AR008880A1 - Compuesto de acido 2-amino carboxilixo 3-alcoxiisoxazol-4-ilo sustituido, composicion farmaceutica que los comprende y uso de los mismos. - Google Patents
Compuesto de acido 2-amino carboxilixo 3-alcoxiisoxazol-4-ilo sustituido, composicion farmaceutica que los comprende y uso de los mismos.Info
- Publication number
- AR008880A1 AR008880A1 ARP970104586A ARP970104586A AR008880A1 AR 008880 A1 AR008880 A1 AR 008880A1 AR P970104586 A ARP970104586 A AR P970104586A AR P970104586 A ARP970104586 A AR P970104586A AR 008880 A1 AR008880 A1 AR 008880A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- pharmaceutical composition
- disease
- alkyl
- ilo
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical class NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 title abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004450 alkenylene group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004419 alkynylene group Chemical group 0.000 abstract 2
- 230000002461 excitatory amino acid Effects 0.000 abstract 2
- 239000003257 excitatory amino acid Substances 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 abstract 1
- 102000003678 AMPA Receptors Human genes 0.000 abstract 1
- 108090000078 AMPA Receptors Proteins 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 239000004215 Carbon black (E152) Substances 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 abstract 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229930195733 hydrocarbon Natural products 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
- 150000003463 sulfur Chemical class 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/12—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Derivados de ácido 2-amino carboxílico sustituido con (3-alcoxiisoxazol-4- -ilo) o análogos de azufre de los mismos que tienen la formula general I o II,en donde R1 es hidrogeno, alquilo, alquenilo, alquinilo, cicloalq(en)ilo, ciloalq(en)il-a lq(en/in)il- alq(en/in)ilo o fenil - alq(en/in)ilooptativamente sustituido; A es un enlace o un grupo espaciador hidrocarburo; B es un grupo -CRa (NRbRc)-COOR5 en donde Ra - Rc son independdientementehidrogeno o alquilo y R5 se define como R1 opiva loiloximetilo, o B es un grupo de formula III, en donde R2, R3 y R4 son independientemente seleccionados entrehidrogeno, un grupo hidrocarburo no aromático, fenil y tienil-alquilo y un grupo heteroalifático, o R3 y R4 están conectaods,formando de ese modo ungrupo alquileno, alquenileno o alquinileno, o R4 y R2 están conectados, formando de ese modo un grupo alquenileno o alquinileno optativamentesustituido con hidroxi o metilo, o para formar CH2-O-CH2; E es COOR6 donde R6 se defi ne como R5, o E es un tetrazolilo o triazolilo; X es O o S; e Y es O oS; son aminoácido excitatorio (EAA), en particular ligandos de receptores AMPA y/o NMDA, utiles en el tratamiento de la isquemia cerebral, enfermedad deHuntington,trastornos epil éptidos, enfermedad de Parkinson, enfermedad de Alzheimer, esquizofrenia, dolor, depresion y ansiedad. Se provee también unacomposicion farmacéutica que los comprende y un uso de los mismos para preparar una composicionfarmacéutica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK109296 | 1996-10-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR008880A1 true AR008880A1 (es) | 2000-02-23 |
Family
ID=8100908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970104586A AR008880A1 (es) | 1996-10-04 | 1997-10-03 | Compuesto de acido 2-amino carboxilixo 3-alcoxiisoxazol-4-ilo sustituido, composicion farmaceutica que los comprende y uso de los mismos. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6200999B1 (es) |
| EP (1) | EP0934286B1 (es) |
| JP (1) | JP2001501630A (es) |
| KR (1) | KR20000048908A (es) |
| CN (1) | CN1238766A (es) |
| AR (1) | AR008880A1 (es) |
| AT (1) | ATE230734T1 (es) |
| AU (1) | AU733004B2 (es) |
| BG (1) | BG103348A (es) |
| BR (1) | BR9712198A (es) |
| CA (1) | CA2268028C (es) |
| CZ (1) | CZ116899A3 (es) |
| DE (1) | DE69718338T2 (es) |
| EA (1) | EA001625B1 (es) |
| ES (1) | ES2189978T3 (es) |
| HU (1) | HUP0000084A3 (es) |
| IL (1) | IL129135A0 (es) |
| IS (1) | IS5009A (es) |
| NO (1) | NO312961B1 (es) |
| NZ (1) | NZ334798A (es) |
| PL (1) | PL332553A1 (es) |
| SK (1) | SK42899A3 (es) |
| TR (1) | TR199900724T2 (es) |
| UA (1) | UA52698C2 (es) |
| WO (1) | WO1998015542A1 (es) |
| ZA (1) | ZA978877B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA73749C2 (en) * | 1999-11-01 | 2005-09-15 | Diarylenines | |
| JP4052573B2 (ja) | 2000-09-15 | 2008-02-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | イソオキサゾールおよびｅｒｋのインヒビターとしてのその使用 |
| US20040106794A1 (en) * | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| UA78529C2 (en) | 2001-10-10 | 2007-04-10 | Wyeth Corp | Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain |
| US20040152694A1 (en) * | 2003-02-04 | 2004-08-05 | Istvan Kurucz | Methods and compositions for treating inflammatory disorders of the airways |
| PT1611144E (pt) | 2003-04-09 | 2010-11-12 | Wyeth Llc | Derivados do ácido 2-(8,9-dioxo-2,6-diazabiciclo(5.2.0)- non-1(7)-eno-2-il)-alquil-fosfónico e sua utilização como antagonistas do receptor n-metil-d-aspartato (nmda) |
| TW200514775A (en) | 2003-10-22 | 2005-05-01 | Wyeth Corp | Methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} phosphonic acid and esters thereof |
| EP1937674A1 (en) * | 2005-10-11 | 2008-07-02 | F.Hoffmann-La Roche Ag | Isoxazole derivatives |
| US8722714B2 (en) | 2008-01-16 | 2014-05-13 | The Honk Kong University of Science and Technology | Oxazolidine derivatives as NMDA antagonists |
| EP2338492A1 (en) | 2009-12-24 | 2011-06-29 | Universidad del Pais Vasco | Methods and compositions for the treatment of alzheimer |
| TW201609719A (zh) * | 2014-05-28 | 2016-03-16 | 美國禮來大藥廠 | 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物 |
| KR102157528B1 (ko) | 2016-01-21 | 2020-09-21 | 아구로카네쇼 가부시키가이샤 | 2-아미노니코틴산 벤질에스테르 유도체의 제조 방법 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE108448T1 (de) | 1990-05-11 | 1994-07-15 | Sankyo Co | Piperdinyloxy- und chinindidinyloxy- isoxazol- derivate, ihre herstellung und ihre therapeutische verwendung. |
| AU678186B2 (en) | 1992-10-23 | 1997-05-22 | Merck Sharp & Dohme Limited | Dopamine receptor subtype ligands |
| DK124393D0 (da) * | 1993-11-03 | 1993-11-03 | Lundbeck & Co As H | Compounds |
-
1997
- 1997-03-10 UA UA99042300A patent/UA52698C2/uk unknown
- 1997-10-03 JP JP10517096A patent/JP2001501630A/ja active Pending
- 1997-10-03 ZA ZA9708877A patent/ZA978877B/xx unknown
- 1997-10-03 KR KR1019990702938A patent/KR20000048908A/ko not_active Ceased
- 1997-10-03 HU HU0000084A patent/HUP0000084A3/hu unknown
- 1997-10-03 PL PL97332553A patent/PL332553A1/xx unknown
- 1997-10-03 CZ CZ991168A patent/CZ116899A3/cs unknown
- 1997-10-03 IL IL12913597A patent/IL129135A0/xx unknown
- 1997-10-03 TR TR1999/00724T patent/TR199900724T2/xx unknown
- 1997-10-03 NZ NZ334798A patent/NZ334798A/en unknown
- 1997-10-03 EP EP97942821A patent/EP0934286B1/en not_active Expired - Lifetime
- 1997-10-03 AT AT97942821T patent/ATE230734T1/de not_active IP Right Cessation
- 1997-10-03 ES ES97942821T patent/ES2189978T3/es not_active Expired - Lifetime
- 1997-10-03 AR ARP970104586A patent/AR008880A1/es not_active Application Discontinuation
- 1997-10-03 BR BR9712198-3A patent/BR9712198A/pt unknown
- 1997-10-03 DE DE69718338T patent/DE69718338T2/de not_active Expired - Fee Related
- 1997-10-03 WO PCT/DK1997/000426 patent/WO1998015542A1/en not_active Ceased
- 1997-10-03 AU AU44517/97A patent/AU733004B2/en not_active Ceased
- 1997-10-03 CN CN97180167A patent/CN1238766A/zh active Pending
- 1997-10-03 US US09/269,356 patent/US6200999B1/en not_active Expired - Fee Related
- 1997-10-03 EA EA199900358A patent/EA001625B1/ru not_active IP Right Cessation
- 1997-10-03 CA CA002268028A patent/CA2268028C/en not_active Expired - Fee Related
- 1997-10-03 SK SK428-99A patent/SK42899A3/sk unknown
-
1999
- 1999-03-20 BG BG103348A patent/BG103348A/xx unknown
- 1999-03-23 IS IS5009A patent/IS5009A/is unknown
- 1999-03-30 NO NO19991561A patent/NO312961B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2268028A1 (en) | 1998-04-16 |
| HUP0000084A3 (en) | 2001-12-28 |
| NZ334798A (en) | 2000-06-23 |
| IL129135A0 (en) | 2000-02-17 |
| US6200999B1 (en) | 2001-03-13 |
| EA001625B1 (ru) | 2001-06-25 |
| SK42899A3 (en) | 1999-08-06 |
| KR20000048908A (ko) | 2000-07-25 |
| IS5009A (is) | 1999-03-23 |
| JP2001501630A (ja) | 2001-02-06 |
| HUP0000084A2 (hu) | 2000-06-28 |
| BR9712198A (pt) | 1999-08-31 |
| WO1998015542A1 (en) | 1998-04-16 |
| AU4451797A (en) | 1998-05-05 |
| EP0934286B1 (en) | 2003-01-08 |
| CN1238766A (zh) | 1999-12-15 |
| BG103348A (en) | 1999-11-30 |
| ATE230734T1 (de) | 2003-01-15 |
| UA52698C2 (uk) | 2003-01-15 |
| NO312961B1 (no) | 2002-07-22 |
| CZ116899A3 (cs) | 1999-09-15 |
| NO991561L (no) | 1999-06-04 |
| AU733004B2 (en) | 2001-05-03 |
| TR199900724T2 (xx) | 1999-06-21 |
| ES2189978T3 (es) | 2003-07-16 |
| NO991561D0 (no) | 1999-03-30 |
| EP0934286A1 (en) | 1999-08-11 |
| EA199900358A1 (ru) | 1999-10-28 |
| PL332553A1 (en) | 1999-09-13 |
| DE69718338T2 (de) | 2003-10-16 |
| ZA978877B (en) | 1998-04-17 |
| CA2268028C (en) | 2003-03-18 |
| DE69718338D1 (de) | 2003-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR008880A1 (es) | Compuesto de acido 2-amino carboxilixo 3-alcoxiisoxazol-4-ilo sustituido, composicion farmaceutica que los comprende y uso de los mismos. | |
| PT946621E (pt) | Polimeros cationicos formadores de pelicula, composicoes contendo os mesmos, e utilizacoes destes, incluindo sistema de libertacao topica e metodo de libertacaode agentes na pele e no cabelo | |
| BR0212481A (pt) | Composto, composição farmacêutica, método de preparação de uma composição farmacêutica, processo para a preparação de um composto, e, uso de um composto | |
| BR0311558A (pt) | composto ou sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, métodos para afetar os receptores de glutamato metabotrópicos ligados a camp, para administrar uma quantidade eficaz de um composto e para tratar um distúrbio neurológico e psiquiátrico em um paciente, e, formulação farmacêutica | |
| ECSP045483A (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso | |
| PT99569A (pt) | Processo para a preparacao de novos derivados de eritromicina e de composicoes farmaceuticas que os contem | |
| DE60234092D1 (de) | Agonisten und antagonisten von sphingosin-1-phosphatrezeptoren | |
| KR960703598A (ko) | 신경 질환 치료제(agent for curing neurotic diseases) | |
| WO2000066564A8 (en) | Benzimidazolones and analogues and their use as progesterone receptor ligands | |
| BR9916282A (pt) | Composto, uso de um um composto e método de tratamento | |
| BRPI0313477B8 (pt) | derivados de purina, composição farmacêutica que os compreende, seu processo de preparação e uso | |
| BR0108600A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, métodos para tratamento de uma doença mediada por quimiocina e para tratamento de uma doença inflamatória | |
| AR029821A1 (es) | Decahidro-isoquinolinas, un proceso para su preparacion, composiciones farmaceuticas que las comprenden y el uso de las mismas para la fabricacion de un medicamento | |
| ATE410412T1 (de) | Oxopyrrolidin verbindungen, verfahren zur herstellung dieser verbindungen und deren verwendung zur herstellung von levetiracetam und analogen | |
| BR9814055A (pt) | Composto, composição farmacêutica, processo para o tratamento de uma doença alérgica, uso do composto, e, processos para preparar e para produzir um composto | |
| AR033996A1 (es) | Una 7-oxo-piridopirimidina, su uso, un proceso para prepararla, una composicion farmaceutica que la comprende, un proceso para producir una pirimidina, un proceso para producir una piridopirimidina, y compuestos preparados mediante dichos procesos | |
| AR004229A1 (es) | Derivados indolalquilo de benzodioxanmetilamina y su uso para preparar medicamentos | |
| NZ522195A (en) | Novel amino carboxy alkyl derivatives of barbituric acid, preparation process and use for treating central nervous system disorders thereof | |
| BR9812236A (pt) | Combinação de componentes, uso desta, processos para a preparação da mesma, para o tratamento de distúrbios afetivos, para o tratamento de depressão, e para melhorar o inìcio de ação terapêutica, formulação farmacêutica, e, kit | |
| KR910000630A (ko) | 할로겐 치환 디페닐 설파이드, 이의 제조방법 및 우울증 치료제로서의 용도 | |
| BR9815920A (pt) | Compostos aza-heterocìclicos usados para tratar distúrbios neurológicos e queda de cabelo | |
| BR9808042A (pt) | Composto, composição farmacêutica, e, processo para preparação de compostos. | |
| RU2003102436A (ru) | Нейропротекторные 7-бета-гидроксистероиды | |
| BR1100306A (pt) | Compostos, composições farmacêuticas, uso de um composto e processo para preparação de compostos | |
| BR9903282A (pt) | Compostos de nitrona, um processo para a preparação dos mesmos e composições farmacêuticas que contêm os mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |